Financial Guidance, Appointments, Board Elections, and Technical Updates - Analyst Notes on Amedisys, Dyax, TearLab, Celladon and Alphatec

NEW YORK, July 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Amedisys Inc. (NASDAQ: AMED), Dyax Corp. (NASDAQ: DYAX), TearLab Corp. (NASDAQ: TEAR), Celladon Corp. (NASDAQ: CLDN) and Alphatec Holdings Inc. (NASDAQ: ATEC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4350-100free.

--
Amedisys Inc. Analyst Notes
On June 27, 2014, Amedisys Inc. (Amedisys) announced its financial outlook for Q2 2014. The Company anticipates quarterly revenues to be in the range of $300 to $305 million, while adjusted EPS from continuing operations is expected to be between $0.15 and $0.20. The Company will discuss the results in detail on its Q2 2014 conference call, which will be held on July 3, 2014, Wednesday at 10:00 a.m. ET (or 9:00 a.m. CT). The full analyst notes on Amedisys are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/AMED/report.pdf

--
Dyax Corp. Analyst Notes
On June 27, 2014, Dyax Corp.'s (Dyax) stock ended the day at $9.96 compared to the previous day's closing price of $8.85, representing a 12.54% growth. The Company's stock has grown 14.22% over the past three trading days, significantly outperforming the Nasdaq Composite which increased 1.09% over the same duration of time. The full analyst notes on Dyax are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/DYAX/report.pdf

--
TearLab Corp. Analyst Notes
On June 13, 2014, TearLab Corp. (TearLab) announced the results from the voting that took place at the annual meeting of shareholders held on June 11, 2014. All of the nominees listed in the management information circular for the annual meeting: Elias Vamvakas, Anthony E. Altig, Thomas N. Davidson Jr., Adrienne Graves, Paul M. Karpecki, Richard L. Lindstrom, Donald E. Rindell, and Brock J. Wright, were elected. Anthony E. Altig had 99.67% favourable votes - the highest amongst the nominees, while Paul M. Karpecki came in next with 99.66% favorable votes and Donald E. Rindell came in third with 99.04% favorable votes. The full analyst notes on TearLab are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/TEAR/report.pdf

--
Celladon Corp. Analyst Notes
On June 9, 2014, Celladon Corp. (Celladon) announced the appointment of Elizabeth E. Reed as the Company's Vice President and General Counsel of the Company. Krisztina Zsebo, Ph.D., CEO of Celladon said, "Elizabeth brings a deep legal background in the biotech industry. Her leadership and guidance in this newly created role will greatly support Celladon's advancement of the MYDICAR program towards commercialization." The Company informed that Ms. Reed has had over 15 years of experience in the legal and biopharmaceutical industry, and served most recently as Senior Vice President, Legal Affairs, General Counsel and Corporate Secretary at Anadys Pharmaceuticals, Inc., until it was acquired by Roche. The full analyst notes on Celladon are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/CLDN/report.pdf

--
Alphatec Holdings Inc. Analyst Notes
On June 27, 2014, Alphatec Holdings Inc. (Alphatec) stock increased 4.35% to end the day at $1.44 compared to the previous day's closing price of $1.38. The Company's stock grew 7.46% over the past three trading days compared to the Nasdaq Composite which increased 1.09% over the same period of time. The full analyst notes on Alphatec are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/ATEC/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED